Voriconazole against fluconazole-susceptible and resistant candida isolates: In-vitro efficacy compared with that of itraconazole and ketoconazole

Journal of Antimicrobial Chemotherapy

Volumn 42, Issue 2, 1998, Pages 253-256

  Nguyen, M Hong ^a,b   Yu, Christine Y ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA TROPICALIS; DRUG RESISTANCE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

EID: 0031826841     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/42.2.253     Document Type: Article

References (10)

1. McGinnis, M. R., Pasarell, L., Sutton, D. A., Fothergill, A. W., Cooper, C. R. & Rinaldi, M. G. (1997). In-vitro evaluation of voriconazole against some clinically important fungi. Antimicrobial Agents and Chemotherapy 41, 1832-4.
2. George, D., Miniter, P. & Andriole, V. T. (1996). Efficacy of UK-109496, a new azole antifungal agent, in an experimental model of invasive aspergillosis. Antimicrobial Agents and Chemotherapy 40, 86-91.
3. Radford, S. A., Johnson, E. M. & Warnock, D. W. (1997). In-vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less common mold pathogens. Antimicrobial Agents and Chemotherapy 41, 841-3.
4. Barry, A. L. & Brown, S. D. (1996). In-vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species. Antimicrobial Agents and Chemotherapy 40, 1948-9.
5. Ruhnke, M., Schmidt-Westhausen, A. & Trautmann, M. (1997). In-vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection. Antimicrobial Agents and Chemotherapy 41, 575-7.
6. Nguyen, M. H., Peacock, J. E., Morris, A. J., Tanner, D. C., Nguyen, M. L., Snydman, D. C. et al. (1996). The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. American Journal of Medicine 100, 617-23.
7. National Committee for Clinical Laboratory Standards. (1995). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. Tentative Standard M27-T. NCCLS, Wayne, PA.
8. Rex, J. H., Pfaller, M. A., Galgiani, J. N., Bartlett, M. S., Espinel-Ingroff, A., Ghannoum, M. A. et al. (1997). Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Clinical Infectious Diseases 24, 235-47.
9. Barchiesi, F., Colombo, A. L., McGough, D. A., Fothergill, A. W. & Rinaldi, M. G. (1994). In-vitro activity of itraconazole against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus. Antimicrobial Agents and Chemotherapy 38, 1530-3.
10. St-Germain, G., Dion, C., Espinel-Ingroff, A., Ratelle, J. & de Repentigny, L. (1995). Ketoconazole and itraconazole susceptibility of Candida albicans isolated from patients infected with HIV. Journal of Antimicrobial Chemotherapy 36, 109-18.